This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A novel mesothelioma molecular classification based on malignant cell differentiation
Cancer Cell International Open Access 24 June 2025
-
Interferon-stimulated gene subtypes as key indicators of immune landscape and survival outcomes in ovarian cancer
Discover Oncology Open Access 18 December 2024
-
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Investigational New Drugs Open Access 01 December 2023
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout

References
Li, X., Song, W., Shao, C., Shi, Y. & Han, W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell. Mol. Immunol. 16, 28–39 (2019).
Lantuejoul, S., Le Stang, N., Damiola, F., Scherpereel, A. & Galateau-Sallé, F. PD-L1 testing for immune checkpoint inhibitors in mesothelioma: for want of anything better? J. Thorac. Oncol. 12, 778–781 (2017).
Mimura, K. et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109, 43–53 (2018).
Kao, S. C. et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J. Thorac. Oncol. 12, 1421–1433 (2017).
Calabrò, L. et al. CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? Cancer Immunol. Immunother. 64, 105–112 (2015).
Frigola, X. et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 17, 1915–1923 (2011).
Gong, B. et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J. Exp. Med. 216, 982–1000 (2019).
Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3+T cells highly expressing PD-L1 and the PD-L1+tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11, 1993–2005 (2016).
Acknowledgements
This work was supported by grants from the Italian Ministry of Health (5x1000 funds 2014 and 2015; Ricerca Corrente 2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Pistillo, M.P., Carosio, R., Banelli, B. et al. IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade. Cell Mol Immunol 17, 410–411 (2020). https://doi.org/10.1038/s41423-019-0245-x
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41423-019-0245-x
This article is cited by
-
A novel mesothelioma molecular classification based on malignant cell differentiation
Cancer Cell International (2025)
-
Interferon-stimulated gene subtypes as key indicators of immune landscape and survival outcomes in ovarian cancer
Discover Oncology (2024)
-
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Investigational New Drugs (2024)
-
Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses
Journal of Translational Medicine (2023)
-
c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation
Nature Cancer (2023)